Antonio Anzueto, MD, professor of medicine and section chief of pulmonary at South Texas Veterans Healthcare System, an affiliated Institution with the University of Texas Health San Antonio, discusses the 2023 GOLD report for COPD. Recommendations include long-acting muscarinic antagonists (LAMA), long-acting beta agonists (LABA), or LAMA+LABA therapy as initial treatment options for most patients with COPD, regardless of the risk of exacerbation.